Raquel de Andrés

5PUBLICATIONS

70CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (5)

Sort by Publication Date:

|May 26, 2026

Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

|Dec 12, 2025

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

|Sep 16, 2024

High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.

Miguel Quintela-Fandino, Begoña Bermejo, Esther Zamora

|Apr 01, 2024

First-line therapy with palbociclib in patients with advanced HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: The real-life study PALBOSPAIN.

N Martínez-Jañez, M Bellet Ezquerra, L M Manso Sanchez

|Jul 12, 2019

Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.

Raquel Andrés, Sebastian Menao, María Arruebo

Pageof 1

Frequent Collaborators

4 joint publications

Noelia Martínez-Jañez

3 joint publications

Emilio Alba

2 joint publications

Luis Manso

2 joint publications

Angel L Guerrero-Zotano

Isabel M Álvarez

Miguel Martín

José J Ponce-Lorenzo

Manuel Ruiz-Borrego

Fernando Moreno

Blanca Hernando

Frequent Collaborators

4 joint publications

Noelia Martínez-Jañez

3 joint publications

Emilio Alba

2 joint publications

Luis Manso

2 joint publications

Angel L Guerrero-Zotano